Johnson & Johnson completes acquisition of V-Wave

Johnson & Johnson on Wednesday announced it completed the previously announced acquisition of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure.

V-Wave will operate as part of Johnson & Johnson MedTech.

New Brunswick-based pharma giant announced in August that it that it agreed to acquire the interatrial shunt maker for up to $1.7 billion.

J&J’s relationship with V-Wave also dates back to an initial investment in the company in 2016.The transaction will be accounted for as an asset acquisition, resulting in an in-process research and development charge of around $600M in the fourth quarter of 2024.

Under the terms of the agreement, New Brunswick-based J&J will pay $600 million upfront, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to another $500 million.

Tim Schmid, executive vice president and Worldwide chairman of Johnson & Johnson MedTech, said, “We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech. V-Wave’s novel implantable device, the Ventura® Interatrial Shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”